Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
AstraZeneca Japan Grows 17% in 2022, Bags 12 Approvals; Up to 7 Filings Eyed for 2023
AstraZeneca enjoyed year-on-year sales growth of 17% in Japan in 2022, driven by new launches as well as its existing portfolio, country president Takafumi Horii said on April 13. The company snared a total of 12 Japanese approvals in the…
To read the full story
Related Article
- AstraZeneca Lifts Japan Approval Target to 50-Plus by 2030 as Pipeline Advances
April 13, 2026
- AstraZeneca Eyes 40 Approvals by 2030 in Japan, Driven by New Modalities
April 15, 2025
- AstraZeneca to Drive Decarbonization by Bolstering EV Infrastructure in Japan
January 24, 2025
- AstraZeneca’s Japan Sales Up 8.2% in 2023 Despite Nexium Patent Cliff
March 27, 2024
- AstraZeneca Japan Taps Ex-Takeda Japan Oncology Head as New Chief
July 4, 2022
- AstraZeneca Ranks Third in Japan Sales Ranking with 12.1% Growth, Good Start in Q1 Too
May 18, 2022
BUSINESS
- Lilly Confirms Orforglipron Diabetes Filings in US, Japan
August 7, 2026
- Takeda Snares US Approval for Orzeyful in Narcolepsy Type 1
August 7, 2026
- Inrebic Expands First-Line Treatment Options for Myelofibrosis: Expert
August 7, 2026
- Meiji Pharma Drops Hiyasta Development in B-Cell NHL
August 7, 2026
- AstraZeneca Japan Chief Says MFN Response Requires Drug Pricing Reform
August 5, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…